TABLE 2.
Comparison between early resistance and non‐early resistance to osimertinib
|
Early resistance (n = 6) a |
Non‐early resistance (n = 42) a |
p | |
|---|---|---|---|
| 70.5 (58–81) | 71.0 (57–85) | 0.943 | |
| Sex | |||
| Female | 6 (17%) | 29 (83%) | 0.108 |
| Male | 0 | 13 (100%) | |
| Smoking status | |||
| Never smoker | 6 (17%) | 30 (83%) | 0.318 |
| Ex or current smoker | 0 | 12 (100%) | |
| Stage | |||
| Ⅲ | 0 | 7 (100%) | 0.578 |
| Ⅳ or recurrence | 6 (15%) | 35 (85%) | |
| Extrathoracic metastasis | |||
| Present | 5 (19%) | 21 (81%) | 0.195 |
| Absent | 1 (5%) | 21 (95%) | |
| EGFR activating mutation | |||
| Ex19 del | 0 | 23 (100%) | 0.010 |
| L858R | 6 (24%) | 19 (76%) | |
| T790 M AF, median (range) | 0.055 (0–45.78) | 0.019 (0–22.5) | 0.384 |
| T790 M AF/Total AF, median (range) | 0.355 (0–0.227) | 0.08 (0–0.414) | 0.704 |
| TP53 SNV | |||
| Present | 5 (19%) | 21 (81%) | 0.199 |
| Absent | 1 (5%) | 21 (95%) | |
| SNV/Indel plus CNV, median (range) | 7 (2–9) | 3 (0–8) | 0.025 |
Abbreviations: AF, allele fraction; CNV, copy number variants; SNV/Indel, single‐nucleotide variants and/or insertion/deletions.
a
Six patients, out of 54 among whom NGS was technically successful, were excluded from the analysis because of discontinuation due to adverse effects or patient's request. Patient characteristics in early resistance and non‐early resistance were compared with the χ2 test for categorical data and the nonparametric Mann–Whitney U test for continuous data.